Major depressive disorder (MDD) affects approximately 280 million people globally and is one of the leading causes of ...

Among patients with narcolepsy, AXS-12 (reboxetine) vs placebo significantly reduced the frequency of cataplexy attacks.

Treatment with esketamine combined with an SNRI is linked to fewer adverse outcomes than treatment with an SSRI alone.

Summary: Duloxetine is a balanced selective serotonin and norepinephrine-reuptake inhibitor available in the United States for the treatment of major depressive disorder (MDD) and diabetic ...

Unlike traditional stimulant medications, which primarily increase dopamine levels through direct release, solriamfetol is a ...

Serotonin-norepinephrine reuptake inhibitors are very similar to SSRIs in that they’re also responsible for increasing serotonin levels. However, they double up by targeting a neurotransmitter ...

The studies investigated serotonin and norepinephrine reuptake inhibitors (SNRIs, eight studies), selective serotonin reuptake inhibitors (SSRIs, two studies), tricyclic antidepressants (TCAs ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease< ...

or serotonin-norepinephrine reuptake inhibitor (SNRI). During the double-blind treatment phase, patients were randomly assigned to receive aticaprant 10mg or placebo once daily, in addition to ...